We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Guidance on Genotoxic Impurities Sets Levels for Experimental Drug
Guidance on Genotoxic Impurities Sets Levels for Experimental Drug
January 13, 2009
Different thresholds for genotoxic and carcinogenic impurities will be set for drugs in clinical development based on the length of time they will be administered to patients in trials, according to an FDA guidance.